These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

532 related items for PubMed ID: 24878193

  • 1. Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
    Kim M, Lee J, Jung K, Kim H, Aman W, Ryu JS, Hah JM.
    Bioorg Med Chem Lett; 2014 Aug 01; 24(15):3600-4. PubMed ID: 24878193
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y, Xin BT, Zhang Y, Wu J, Lu X, Zheng Y, Tang W, Zhou X.
    Eur J Med Chem; 2015 Jan 27; 90():170-83. PubMed ID: 25461318
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Design and synthesis of novel 2-(4-(2-(dimethylamino)ethyl)-4H-1,2,4-triazol-3-yl)pyridines as potential antitumor agents.
    Qin M, Zhai X, Xie H, Ma J, Lu K, Wang Y, Wang L, Gu Y, Gong P.
    Eur J Med Chem; 2014 Jun 23; 81():47-58. PubMed ID: 24826815
    [Abstract] [Full Text] [Related]

  • 5. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
    Henry JR, Kaufman MD, Peng SB, Ahn YM, Caldwell TM, Vogeti L, Telikepalli H, Lu WP, Hood MM, Rutkoski TJ, Smith BD, Vogeti S, Miller D, Wise SC, Chun L, Zhang X, Zhang Y, Kays L, Hipskind PA, Wrobleski AD, Lobb KL, Clay JM, Cohen JD, Walgren JL, McCann D, Patel P, Clawson DK, Guo S, Manglicmot D, Groshong C, Logan C, Starling JJ, Flynn DL.
    J Med Chem; 2015 May 28; 58(10):4165-79. PubMed ID: 25965804
    [Abstract] [Full Text] [Related]

  • 6. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
    Zhang Q, Wang J, Wang F, Chen X, He Y, You Q, Zhou H.
    Chem Biol Drug Des; 2014 Jan 28; 83(1):27-36. PubMed ID: 24164966
    [Abstract] [Full Text] [Related]

  • 7. Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies.
    Fu Y, Wang Y, Wan S, Li Z, Wang G, Zhang J, Wu X.
    Molecules; 2017 Mar 29; 22(4):. PubMed ID: 28353640
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAFV600E/p38α inhibitors.
    Ali EMH, El-Telbany RFA, Abdel-Maksoud MS, Ammar UM, Mersal KI, Zaraei SO, El-Gamal MI, Choi SI, Lee KT, Kim HK, Lee KH, Oh CH.
    Eur J Med Chem; 2021 Apr 05; 215():113277. PubMed ID: 33601311
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAFV600E and VEGFR-2 dual inhibitors.
    Wang Y, Wan S, Li Z, Fu Y, Wang G, Zhang J, Wu X.
    Eur J Med Chem; 2018 Jul 15; 155():210-228. PubMed ID: 29886324
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAFV600Einhibitors.
    Ali EMH, Abdel-Maksoud MS, Ammar UM, Mersal KI, Ho Yoo K, Jooryeong P, Oh CH.
    Bioorg Chem; 2021 Jan 15; 106():104508. PubMed ID: 33280830
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
    Wang SF, Zhu YL, Zhu PT, Makawana JA, Zhang YL, Zhao MY, Lv PC, Zhu HL.
    Bioorg Med Chem; 2014 Nov 01; 22(21):6201-8. PubMed ID: 25267006
    [Abstract] [Full Text] [Related]

  • 13. New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies.
    Choi WK, El-Gamal MI, Choi HS, Baek D, Oh CH.
    Eur J Med Chem; 2011 Dec 01; 46(12):5754-62. PubMed ID: 22014559
    [Abstract] [Full Text] [Related]

  • 14. Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent aurora A kinase inhibitors.
    Luo Y, Deng YQ, Wang J, Long ZJ, Tu ZC, Peng W, Zhang JQ, Liu Q, Lu G.
    Eur J Med Chem; 2014 May 06; 78():65-71. PubMed ID: 24681066
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis, in vitro antiproliferative evaluation, and kinase inhibitory effects of a new series of imidazo[2,1-b]thiazole derivatives.
    Abdel-Maksoud MS, Kim MR, El-Gamal MI, Gamal El-Din MM, Tae J, Choi HS, Lee KT, Yoo KH, Oh CH.
    Eur J Med Chem; 2015 May 05; 95():453-63. PubMed ID: 25841200
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors.
    Yang W, Chen Y, Zhou X, Gu Y, Qian W, Zhang F, Han W, Lu T, Tang W.
    Eur J Med Chem; 2015 Jan 07; 89():581-96. PubMed ID: 25462267
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Structure-based design and synthesis of novel pseudosaccharine derivatives as antiproliferative agents and kinase inhibitors.
    Elsayed MS, El-Araby ME, Serya RA, El-Khatib AH, Linscheid MW, Abouzid KA.
    Eur J Med Chem; 2013 Mar 07; 61():122-31. PubMed ID: 23063746
    [Abstract] [Full Text] [Related]

  • 19. Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.
    El-Damasy AK, Lee JH, Seo SH, Cho NC, Pae AN, Keum G.
    Eur J Med Chem; 2016 Jun 10; 115():201-16. PubMed ID: 27017549
    [Abstract] [Full Text] [Related]

  • 20. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
    Wang Y, Liu WJ, Yin L, Li H, Chen ZH, Zhu DX, Song XQ, Cheng ZZ, Song P, Wang Z, Li ZG.
    Bioorg Med Chem Lett; 2018 Mar 01; 28(5):974-978. PubMed ID: 29429832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.